Autres langues BioNTech SE

Actions

BNTX

US09075V1026

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 10/06/2024			Varia. 5j.	Varia. 1 janv.
97,98 ^USD	-2,35 %		-4,75 %	-7,16 %

17:15	Les actions européennes négociées aux États-Unis sous la forme de certificats de dépôt américains sont en baisse lundi matin	MT
08:24	L'Indonésie intensifie la lutte contre la tuberculose en raison des inquiétudes concernant l'impact économique	RE

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

European Equities Traded in the US as American Depositary Receipts Lower in Monday Trading	17:15
Indonesia ramps up fight against tuberculosis amid concerns on economic impact	08:24
European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading	05/06
COVID shots for JN.1 variant neutralize newer strains, vaccine makers say	05/06
BioNTech : ASCO 2024	03/06
European Equities Traded in the US as American Depositary Receipts Fall in Monday Trading	03/06
GNW-Adhoc: Phase-2-Daten für Prüfpräparat Acasunlimab (DuoBody® -PD-L1x4-1BB) in Kombination mit Pembrolizumab: Signifikante klinische Aktivität bei vorbehandeltem, metastasiertem nicht-kleinzelligem Lungenkarzinom	01/06
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)	01/06
Genmab A/S and Biontech SE Announce Initial Data from the Phase 2 Gct1046-04 Trial (NCT05117242) Evaluating Acasunlimab	01/06
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)	01/06
Phase-2-Daten für Prüfpräparat Acasunlimab (DuoBody® -PD-L1x4-1BB) in Kombination mit Pembrolizumab: Signifikante klinische Aktivität bei vorbehandeltem, metastasiertem nicht-kleinzelligem Lungenkarzinom	01/06
European Equities Traded in US as American Depositary Receipts Rise Friday, Poised to End Week Lower	31/05
Patents, Policies And Privacy: The Highs And Lows Of Technology In IP	31/05
Dyadic International Inc. (DYAI): Bird Flu Vaccine Development Amid Rising Pandemic Concerns	30/05
BioNTech : Publication of the resolutions and system for the remuneration of Supervisory Board Members (resolution of the AGM on 17 May 2024)	30/05
BioNTech : Publication of the resolutions and system for the remuneration of Supervisory Board Members (resolution of the AGM on 1 June 2022)	30/05
BioNTech : Publication of the resolutions and system for the remuneration of Supervisory Board Members (resolution of the AGM on 22 June 2021)	30/05
BioNTech : Publication of the resolutions and system for the remuneration of the members of the management Board (resolution of the AGM on 17 May 2024)	30/05
BioNTech, CEPI Expand Partnership for mRNA Vaccine Ecosystem in Africa	29/05
Keine Corona-Impfpflicht mehr für Soldaten - Bundesgericht am Zug	29/05

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

A la une

BIONTECH : Un raté est un raté

Le 21 mars 2024 à 14:27

BioNTech SE : Valorisation à la casse

Le 21 mars 2024 à 09:28